2025 · 1st Quarter (Jan 1 - Mar 31)
Filed by EDWARDS LIFESCIENCES, LLC.
Open official filingSource-reported fields
Expense method: A
Literal source text
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Literal federal measure citations: H.R.1691, S.5349
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Literal federal measure citations: H.R.1691, S.5349
Corporate Tax Reform Proposals
Tariffs
Veterans Access to MedTech
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
